An Act to bring down the cost of prescription drugs

This bill directs the Massachusetts Health Policy Commission to study the feasibility of creating a state-run program to manufacture generic and biosimilar prescription drugs. The study will analyze how such a program could increase competition, lower prices, and address drug shortages for public and private payers. Commission members must submit a report with findings, cost-benefit analysis, and recommendations to state officials within one year of the bill's passage.